XML 33 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
The Company and Summary of Significant Accounting Policies (Details Textual)
 3 Months Ended 12 Months Ended
Mar. 31, 2017
USD ($)
Patients
shares
Dec. 31, 2016
USD ($)
shares
Dec. 31, 2015
USD ($)
shares
Jan. 11, 2017
USD ($)
Company And Summary Of Significant Accounting Policies Table [Line Items]        
Revenues $ 0      
Common stock, shares issued | shares 9,172,868 9,082,366    
Proceeds from sale of common stock $ 210,000      
Concentrations of credit risk $ 0      
Excess tax benefits from share-based payments   $ 0 $ 0  
Number of shares withhold to satisfy statutory income tax withholding obligations | shares   0 0  
At the Market Offering under Sales Agreement        
Company And Summary Of Significant Accounting Policies Table [Line Items]        
Aggregate offering price of common stock authorized       $ 7,300,000
Common stock, shares issued | shares 85,068      
Proceeds from sale of common stock $ 221,000      
Net proceeds from issuance of common stock $ 69,000      
Phase 3 | BEST Trial        
Company And Summary Of Significant Accounting Policies Table [Line Items]        
Number of patients | Patients 2,708      
Phase 2B/Phase 3 | GENETIC-AF Trial        
Company And Summary Of Significant Accounting Policies Table [Line Items]        
Number of patients company plans to enroll | Patients 620      
Trial endpoint, term 168 days